Rezolute's Stock Plummets 87.2% Following Phase 3 Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Globenewswire
- Clinical Trial Results Disappoint: Rezolute's Phase 3 sunRIZE study evaluating ersodetug failed to meet its primary endpoint, with a 45% reduction in hypoglycemia events at the highest dose showing no statistical significance compared to the placebo group's 40% improvement, indicating insufficient drug efficacy.
- Stock Price Plummets: Following the trial results announcement, Rezolute's stock price fell by $9.44, or 87.2%, closing at $1.77 per share on December 19, 2025, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Rezolute engaged in securities fraud or other unlawful business practices, which could negatively impact the reputation of the company's management and its future operations.
- Investor Reaction Strong: The failure to meet key trial endpoints has severely shaken investor confidence in Rezolute, potentially leading to reduced financing and partnership opportunities, thereby affecting the company's long-term strategic development.
Analyst Views on RZLT
Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 16.14 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.190
Low
12.00
Averages
16.14
High
20.00
Current: 2.190
Low
12.00
Averages
16.14
High
20.00
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
